Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Chaccour
  NCT04390022		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

COVID 19 outpatients meta-analysis

ACTIV-6 (ivermectine)
  NCT04885530		 RCTivermectinplaceboCOVID 19 outpatientslow
602/604 inconclusive
    ACTIV 6 ivermectin
          NCT04885530    		 RCTivermectinplaceboCOVID 19 outpatientslow
    		817/774 inconclusive
      ACTIV-6
              NCT04885530      		 RCTfluvoxamineplaceboCOVID 19 outpatientslow
      		674/614 inconclusive
      • inconclusive 4 % decrease in recovery (PE) with a high degree of certainty due to low risk of bias
      COVID-OUT (fluvoxamine)
              NCT04510194      		 RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
      		334/327 inconclusive
      • inconclusive 6 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
      COVID-OUT (ivermectin)
              NCT04510194      		 RCTivermectinplaceboCOVID 19 outpatientssome concern
      		410/398 inconclusive
        TOGETHER (ivermectine)
                  NCT04727424        		 RCTivermectinplaceboCOVID 19 outpatientslow
        		679/679 inconclusive
        • inconclusive 10 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
        ACTION
                  NCT04332107        		 RCTazithromycinplaceboCOVID 19 outpatientssome concern
        		171/92 inconclusive
        • inconclusive 1 % increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        The original primary outcome was changed given the lower risk of hospitalization and slower than anticipated enrollment.
        EPIC-HR
                  NCT04960202        		 RCTnirmatrelvir / ritonavir (Paxlovid)placeboCOVID 19 outpatientslow
        		1120/1126 conclusif
        • demonstrated 88 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
        • suggested 96 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias
        • statistically significant 76 % increase in related AE (TRAE) with a high degree of certainty due to low risk of bias
        Based on laboratory studies only, Paxlovid is also expected to be active against Omicron and other variants.
        Fischer (all doses)
                  NCT04405570        		 RCTmolnupiravirplaceboCOVID 19 outpatientssome concern
        		140/62 suggested
        • suggested 13.5-fold increase in viral clearance ,viral clearance by day 7 with a moderate degree of certainty due to some concern in risk of bias
        Hinks (ATOMIC2)
                  NCT04381962        		 RCTazithromycinstandard of careCOVID 19 outpatientssome concern
        		147/148 inconclusive
        • inconclusive 9 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
        Lopez-Medina
                  NCT04405843        		 RCTivermectinplaceboCOVID 19 outpatientssome concern
        		200/200 inconclusive
        • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        MOVe-OUT
                  NCT04575597        		 RCTmolnupiravirplaceboCOVID 19 outpatientslow
        		716/717 conclusif
        • demonstrated 52 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
        • suggested 51 % decrease in hospitalization with a high degree of certainty due to low risk of bias
        PINETREE (GS-US-540-9012)
                  NCT04501952        		 RCTremdesivirplaceboCOVID 19 outpatientslow
        		292/292 conclusif
        • demonstrated 87 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
        • suggested 72 % decrease in hospitalization with a high degree of certainty due to low risk of bias
        PRINCIPLE
                  ISRCTN86534580        		 RCTazithromycinstandard of careCOVID 19 outpatientssome concern
        		540/875 inconclusive
        • inconclusive 8 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • inconclusive 6 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
        Reis (Lopinavir-ritonavir) (TOGETHER)
                  NCT04403100        		 RCTlopinavir/ritonavirplaceboCOVID 19 outpatientssome concern
        		244/227 inconclusive
          Thomas (zinc only)
                      NCT04342728          		 RCTzincstandard of careCOVID 19 outpatientsNA
          		58/50 inconclusive
            TOGETHER
                          NCT04727424            		 RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
            		741/756 suggested
            • suggested 36 % decrease in clinical deterioration,emergency room observation for > 6 hours or hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
            Chowdhury A
                          NCT04434144            		 RCTdoxycyclinehydroxychloroquine plus macrolidesCOVID 19 outpatientshigh
            		60/56 no results
              Chowdhury A
                              NCT04434144              		 RCTivermectinhydroxychloroquine plus macrolidesCOVID 19 outpatientshigh
              		60/56 no results
                IVERCORCOVID19 (Vallejos)
                                  NCT04529525                		 RCTivermectinplaceboCOVID 19 outpatientslow
                		250/251 inconclusive
                • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias
                Lenze (STOP COVID 1)
                                  NCT04342663                		 RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
                		80/72 conclusif
                • demonstrated 93 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                Podder RCTivermectinstandard of careCOVID 19 outpatientshigh
                		32/30 inconclusive
                  Roozbeh
                                      IRCT20200403046926N1                  		 RCTsofosbuvir and daclatasvirstandard of careCOVID 19 outpatients
                  bias due to missing outcome data some concern
                  bias in measurement of the primary outcome some concern
                  bias in selection of the reported result some concern
                  " >some concern
                  30/30 inconclusive Chahla
                                      NCT04784481 CRTivermectinstandard of careCOVID 19 outpatientshigh
                  110/144 suggested 2 studies excluded by filtering options (0 RCT / 2 OBS)

                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                   

                  - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons